Calithera to Present New Phase 1 Solid Tumor Dose Expansion Data of CB-839 at the 2015 AACR-NCI-EORTC International Conference

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Calithera to Present New Phase 1 Solid Tumor Dose Expansion Data of CB-839 at the 2015 AACR-NCI-EORTC International Conference

Leerink Partners Reiterates Outperform on Calithera Biosciences (CALA) Following 3Q

November 10, 2015 7:00 AM EST

Leerink Partners reiterated an Outperform rating and $13.00 price target on Calithera Biosciences (NASDAQ: CALA) following the company's 3Q earnings report. CALA reported 3Q15 EPS of ($0.49), slightly better than consensus estimates of ($0.54).

Analyst Paul Matteis commented, "After the close, CALA reported 3Q15 EPS of ($0.49), in-line with... More

Calithera Biosciences (CALA) Updates on CB-839 at 2015 AACR-NCI-EORTC

November 9, 2015 8:46 AM EST

Calithera Biosciences (NASDAQ: CALA) to announce new clinical data from the solid tumor expansion cohorts of its lead anti-cancer therapeutic candidate, CB-839, at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets in Boston, Massachusetts. CB-839 is a potent, selective, orally bioavailable glutaminase inhibitor in phase I clinical trials. The data support earlier findings of the clinical activity, tolerability and unique mechanism of action of CB-839 in patients with solid tumors, as well as show one partial response according to RECIST criteria.

The new data to be presented by Funda Meric-Bernstam, MD, from MD Anderson Cancer... More